Type 2 diabetes is a chronic disease that affects millions of people worldwide. It is characterized by high levels of sugar in the blood due to the body's cells resisting the normal effect of insulin, a hormone produced by the pancreas. When left untreated, this condition can lead to serious complications such as nerve damage, kidney damage, and cardiovascular disease. Fortunately, there are a variety of treatment options available to manage type 2 diabetes, including lifestyle changes, medications, and insulin therapy.
One of the newest medications available for the treatment of type 2 diabetes is Brenzavvy (bexagliflozin), a prescription medicine used along with diet and exercise to improve blood sugar (glucose) in adults with type 2 diabetes. Brenzavvy belongs to the class of drugs called sodium-glucose co-transporter 2 (SGLT2) inhibitors. It works by reducing renal reabsorption of filtered glucose and lowering the renal threshold for glucose, thereby increasing urinary glucose excretion.
We asked the Type 2 diabetes treaters from the ZoomRx panel to give us their first impressions of the drug. Out of the 30 survey respondents, only 9 were aware of Brenzavvy.
The HCPs who were aware of Brenzavvy had varying opinions on its potential benefits. Some viewed it as a promising option for treating Type 2 diabetes and welcomed the introduction of alternative treatments, while others felt that it did not offer any significant advantages over existing medications in the SGLT2 inhibitor class.
One HCP stated, "I think it is another promising diabetic drug," while another commented, "I do not see any advantage of Brenzavvy to any available SGLT2 products in the market. It actually has no data on cardiovascular or renal indication that the other SGLT2 products have."
Overall, Brenzavvy has low awareness among HCPs & may have little potential in the competitive Type 2 diabetes space. As more information becomes available on its efficacy and safety, it remains to be seen whether Brenzavvy will gain greater acceptance and adoption among diabetes treaters.